Brian D. Conn Named Interim CFO at Ra Medical Systems

Ra Medical Systems Inc. has appointed Brian D. Conn as interim chief financial officer (CFO). He will serve as the company’s principal financial officer and principal accounting officer.
 
Conn has been a consultant to Ra Medical since May 25. He replaces Will McGuire, who was appointed interim CFO on July 8, 2022, following the departure of Andrew Jackson, the company’s former CFO, on May 25, 2022. McGuire will continue as CEO and director of the company.
 
“We are fortunate to have a professional with Brian’s extensive and highly relevant experience step into our senior financial position as our board of directors continues to assess strategic alternatives with the goal of maximizing value for Ra Medical’s stockholders,” said McGuire.
 
Conn has held senior-level financial positions in both public and private companies for more than 25 years, including serving as CFO at several medical device companies. He has managed all financial aspects of businesses and is proficient in SEC reporting and compliance requirements. Conn was previously CFO of Quantapore Inc., a genomic sequencing startup, where he continues to serve as an advisor. He was also CFO of Imagion Biosystems Limited, a preclinical medical imaging company; CFO of Verdezyne Inc., a privately held biotechnology company; and an advisor to numerous early-stage biotechnology companies.

Conn earned his bachelor of science degree in finance and a minor in accountancy from Arizona State University.
 
Ra Medical Systems manufactures the DABRA excimer laser and catheters to treat certain vascular diseases. DABRA has been cleared by the U.S. Food and Drug Administration for crossing chronic total occlusions in patients with symptomatic infrainguinal lower extremity vascular disease and has an intended use for ablating a channel in occlusive peripheral vascular disease. In addition, DABRA has been granted CE mark clearance for the endovascular treatment of infrainguinal arteries via atherectomy and for crossing total occlusions. DABRA excimer lasers and catheters are manufactured in a 32,000-square-foot facility located in Carlsbad, Calif. The vertically integrated facility is ISO 13485 certified and is licensed by the State of California to manufacture sterile, single-use catheters in clean room environments.